MYCN-directed centrosome amplification requires MDM2-mediated suppression of p53 activity in neuroblastoma cells

Andrew D Slack1, Zaowen Chen, Andrew D Ludwig

  • 1Center for Cell and Gene Therapy, Texas Children's Cancer Center, Baylor College of Medicine, Houston, Texas 77030, USA.

Cancer Research
|March 17, 2007
PubMed

Insights

MYCN oncogene drives neuroblastoma tumor growth by causing centrosome amplification, a key factor in genomic instability. MDM2 protein mediates this effect, highlighting a potential therapeutic target for neuroblastoma treatment.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • MYC family oncogenes, including MYCN, are crucial drivers of tumor progression and genomic instability.
  • Centrosome amplification, linked to mitotic defects and karyotypic instability, is observed in MYCN-expressing neuroblastoma cells.
  • The precise mechanisms by which MYCN induces centrosome amplification remain incompletely understood.

Purpose of the Study:

  • To investigate the role of MDM2 in MYCN-mediated centrosome amplification and genomic instability in neuroblastoma.
  • To determine if p53 pathway modulation affects MYCN-induced centrosome amplification.

Main Methods:

  • Utilized neuroblastoma cell lines with varying MYCN expression levels.
  • Employed ionizing radiation to induce DNA damage and assess centrosome amplification.
  • Investigated the effect of MDM2 modulation (overexpression and RNA interference) and p53-MDM2 interaction inhibition (Nutlin 3A) on centrosome amplification.
  • Correlated centrosome amplification with MYCN amplification in primary neuroblastoma tumors.

Main Results:

  • MYCN expression mediates centrosome amplification in a p53-dependent manner.
  • Inhibition of the p53-MDM2 interaction with Nutlin 3A abrogated MYCN-dependent centrosome amplification.
  • MDM2 overexpression or inhibition significantly modulated centrosome amplification in MYCN-expressing cells, establishing MDM2 as a necessary and sufficient mediator.
  • A significant correlation was found between centrosome amplification and MYCN amplification in primary neuroblastoma tumors.

Conclusions:

  • MDM2 is a critical mediator of MYCN-induced centrosome amplification in neuroblastoma.
  • Targeting the p53-MDM2 interaction may represent a therapeutic strategy to reduce MYCN-driven genomic instability in neuroblastoma.
  • Elevated MDM2 levels contribute to MYCN-induced genomic instability by dysregulating centrosome replication.

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Induced Pluripotent Stem Cells01:06

Induced Pluripotent Stem Cells

Stem cells are undifferentiated cells that divide and produce different cell types. Ordinarily, cells that have differentiated into a specific cell type are terminally differentiated; however, scientists have found a way to reprogram these mature cells so that they dedifferentiate and return to an unspecialized, proliferative state. These cells are pluripotent like embryonic stem cells—able to produce all cell types—and are called induced pluripotent stem cells (iPSCs).
Somatic cells are...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Negative Regulator Molecules01:23

Negative Regulator Molecules

Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
Centrosome Duplication02:25

Centrosome Duplication

The primary microtubule organizing center (MTOC) in animal cells is the centrosome. A centrosome has two cylindrical centrioles at its core. Each centriole consists of nine sets of three microtubules held together by proteins. The centrioles are positioned at right angles to each other and surrounded by a shapeless protein cloud called the pericentriolar matrix, or pericentriolar material (PCM).
To ensure that each daughter cell receives a centrosome after cell division, centrosome duplication...
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...